Edition:
India

GSK Long-Acting HIV Injection Meets Goal In Late Stage Study


Thursday, 22 Aug 2019 

Aug 22 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE PLC - VIIV RESULTS POSITIVE FOR EVERY 2 MONTH INJECTION.GSK- PHASE III STUDY RESULTS OF INVESTIGATIONAL, LONG-ACTING, INJECTABLE HIV-TREATMENT TWO MONTHS REGIMEN ATLAS-2M STUDY MET ITS PRIMARY ENDPOINT.GLAXOSMITHKLINE PLC - DETAILED RESULTS FROM ATLAS-2M STUDY WILL BE PRESENTED AT AN UPCOMING SCIENTIFIC MEETING.